Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons

12005,146

18/126251

March 24, 2023

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

THERASYN SENSORS, INC (Eggertsville, NY, US)

THERASYN SENSORS, INC. (Eggertsville, NY, US)

1. A method of treating a patient or subject in need of treatment of a disease state or condition comprising administering to said patient or subject a composition comprising one or more active molecules encapsulated in a liquid vesicle to provide an intact loaded vesicle wherein the outer surface coating of said loaded vesicle comprises at least one cholesteryl ester obtained from cholesterol and a C 6 -C 26 fatty acid, said molecules obtaining in an effective amount an intracellular concentration in target cells of said patient or subject which is at least 2-fold greater than the concentration obtained by said molecules in the absence of said coating, wherein said molecules are selected from the group consisting of small molecules, proteins, monoclonal antibodies, peptides, polynucleotides, oligonucleotides, nucleic acids and mixtures thereof, wherein said administration includes at least one oral, parenteral or topical dosage form and said outer surface coating of said loaded vesicle remains intact during passage of said loaded vesicle across a membrane of a cell in said patient or subject and wherein said vesicle optionally releases said one or more molecules inside target cells by the action of cholesteryl ester hydrolases on said vesicle, and said disease state or condition is asthma, cancer, arthritis, Crohn's disease, multiple sclerosis, hyperlipidemia, obesity, type II diabetes, psoriasis, pulmonary arterial hypertension (PAH), inflammation, an intracellular viral, bacterial or fungal infection.

2. The method according to claim 1 wherein said disease state or condition is inflammation and said molecule is a compound selected from the group consisting of tocilizumab, adalimumab, etanercept, infliximab or combinations of at least two of said molecules, wherein said administration is by oral or parenteral dosage form.

3. The method according to claim 2 , wherein said disease state or condition is a bacterial or viral infection and said molecule is tocilizumab, wherein said administration is by oral or parenteral dosage form.

4. The method according to claim 1 wherein said disease state or condition is cancer and said molecule is bevacizumab, wherein said administration is by oral or parenteral dosage form.

5. The method according to claim 1 wherein said disease state or condition is cancer and said molecule is a compound selected from the group consisting of nivolumab, ipilimumab, or a combination of nivolumab and ipilimumab, wherein said administration is by oral or parenteral dosage form.

6. The method according to claim 1 wherein said disease state or condition is cancer and said molecule is a compound selected from the group consisting of pembrolizumab, ipilimumab, tremelimumab or a combination of pembrolizumab and either ipilimumab or tremelimumab, wherein said administration is by oral or parenteral dosage form.

7. The method according to claim 1 wherein said disease state or condition is cancer and said molecule is pembrolizumab, wherein said administration is by oral or parenteral dosage form.

8. The method according to claim 1 wherein said disease state or condition is cancer and said molecule is a compound selected from the group consisting of alemtuzumab, ipilimumab, or a combination of alemtuzumab and ipilimumab, wherein said administration is by oral or parenteral dosage form.

9. The method according to claim 1 wherein said disease state or condition is cancer and said molecule is a compound selected from the group consisting of trastuzumab, or T-DM1, wherein said T-DM1 is trastuzumab linked to emtansine, wherein said administration is by oral or parenteral dosage form.

10. The method according to claim 1 wherein said disease state or condition is Crohn's disease and said molecule is ustekinumab, wherein said dosing form is by oral capsule with coating to release ustekinumab in said patient's ileum.

11. The method according to claim 1 wherein said disease state or condition is Crohn's disease and said molecule is adalimumab, wherein said dosing form is by oral capsule with coating to release adalimumab in said patient's ileum.

12. The method according to claim 1 wherein said disease state or condition is Crohn's disease and said molecule is infliximab, wherein said dosing form is by oral capsule with coating to release infliximab in said patient's ileum.

13. The method according to claim 1 wherein said disease state or condition is Crohn's disease and said molecule is etanercept, wherein said dosing form is by oral capsule with coating to release etanercept in said patient's ileum.

14. The method according to claim 1 wherein said disease state or condition is multiple sclerosis and said molecule is natalizumab, wherein said administration is by oral or parenteral dosage form.

15. The method according to claim 1 wherein said disease state or condition is multiple sclerosis and said molecule is alemtuzumab, wherein said administration is by oral or parenteral dosage form.

16. The method according to claim 1 wherein said disease state or condition is psoriasis, psoriatic arthritis, or arthritis and said molecule is secukinumab, wherein said administration is by oral or parenteral dosage form.

17. The method according to claim 1 wherein said disease state or condition is type 2 diabetes or obesity and said molecule is a GLP-1 hydrophilic peptide, wherein said administration is by oral or parenteral dosage form.

18. The method according to claim 1 wherein said disease state or condition is allergic asthma and said molecule is omalizumab, wherein said administration is by oral or parenteral dosage form.

19. The method according to claim 1 wherein said disease state or condition is allergic asthma and said molecule is dupilumab, wherein said administration is by oral or parenteral dosage form.

20. The method according to claim 1 wherein said disease state or condition is allergic asthma and said molecule is benralizumab, wherein said administration is by oral or parenteral dosage form.

4544545 October 1985 Ryan et al.
5013556 May 1991 Woodle et al.
5049389 September 1991 Radhakrishnan
5094854 May 1992 Ogawa et al.
5288499 February 1994 Janoff et al.
5844075 December 1998 Kawakami et al.
9119782 September 2015 McCourt
9693969 July 2017 Skigen
10092516 October 2018 McCourt
10369114 August 2019 Schentag et al.
20040037874 February 2004 Hong
20040052838 March 2004 Naeff et al.
20040197393 October 2004 Smyth-Templeton et al.
20060216255 September 2006 Lee et al.
20060286161 December 2006 Panzner et al.
20070014840 January 2007 Lee et al.
20070225264 September 2007 McCourt
20080241257 October 2008 Popescu et al.
20110046053 February 2011 Kidron
20130183270 July 2013 Geho
20140199233 July 2014 Nagy
20190060236 February 2019 McCourt
20190175515 June 2019 Schentag et al.
2009143963 July 2009
9203123 March 1992
2004098564 November 2004
2013148258 October 2013
2014152795 September 2014
2016156398 April 2016

Giguere S, et al. Role of the 85-Kilobase Plasmid and Plasmid-Encoded Virulence-Associated Protein A in Intracellular Survival and Virulence of Rhodococcus equi. Infection and Immunity, 1999;67(7):3548-3557. cited by applicant
Yoshida K, et al. Effect of Tumor Size on Monoclonal Antibody Uptake in a Metastatic Model. Journal of Surgical Oncology, 1992;49:249-252. cited by applicant
Bussiere JL, et al. 60-Day Repeated Dose Inhalation Toxicity Study of an Anti-IgE Antibody in Cynomolgus Monkeys. SOT Annual Meeting, 1997;271. cited by applicant
Sweeney TD, et al. Pulmonry Delivery of Anti-IgE Rationale for Topical Delivery to the Airway, 2001. cited by applicant
Bleavins MR, et al. Cynomolgus monkeys (Macaca fascicularis) in preclinical immune function safety testing: development of a delayed-type hypersensitivity procedure. Toxicology, 1995;95:103-112. cited by applicant
Ryffel B. Impact of Knockout Mice in Toxicology. Critical Reviews in Toxicology, 1997;27(2):135-154. cited by applicant
Congestive Heart Failure. American Heart Association (2006) http://www.americanheart.org/presenter.jhtml?identifier=4585. cited by applicant
Heart Attack, Stroke & Cariac Arrest Warning Sings. American Heart Association (2006) http://www.americanheart.org/presenter.jhtml?identifier=3053. cited by applicant
Bjorkhlem I, et al. Oxysterols: Friends, Foes or Just Fellow Passengers? Arteriosclerosis, Thrombosis, and Vascular Biology, 2002;22:734-742. cited by applicant
Christiansen LI. Preparation, Analysis and Cholesterol Lowering Effect of a Novel Microcrystalline . . . Suspension in Oil and Phase Behavior of Beta-sitosterol with Cholesterol. Academic Dissertation at the University of Helsinki, Finland (2002). cited by applicant
Dorset DL, et al. Co-solubility in binary phospohlipid crystals. Biochimica et Biophysica Acta, 1987;903:319-332. cited by applicant
Dorset DL. Cholesteryl esters of saturated fatty acids: cosolubility and fractionation of binary mixtures. Journal of Lipid Research, 1987;28:993-1005. cited by applicant
Dorset DL. Co-solubility of saturated cholesteryl esters: a comparison of calculated and experimental binary phase diagrams. Biochimica et Biophysica Acta, 1988;963:88-98. cited by applicant
Dorset DL. Binary phase behavior of cholestryl oleate with cholesteryl linoleate. Biochimica et Biophysica Acta, 1990;1046:57-63. cited by applicant
Dorset DL. Eutectic interactions in binary systems containing cholesterol, cholesteryl esters and triacylgycerols. Biochimica et Biophysica Acta, 1990;1047:112-120. cited by applicant
Dorset DL. Binary phase behavior of angiotoxic oxidized cholesterols with cholesterol. Biochimica et Biophysica Acta, 1992;1127:293-297. cited by applicant
Garcia-Cruset S, et al. Oxysterols in cap and core oh human advanced atherosclerotic lesions. Free Radical Research, 1999;30:341-351. cited by applicant
Guo W, et al. Phase Behavior and Crystalline Structures of Cholesteryl Ester Mixtures: A C-13 MASNMR Study. Biophysical Journal, 1995;68:341-351. cited by applicant
Hulten LM, et al. Oxysterols persent in atherosclerotic tissue decrease the expression of lipoprotein fipase messenger RNA inhuman monocyte-derived macrophages. The Journal of Clinical Investigation, 1996;97:461-468. cited by applicant
Leoni V. On the possible use of oxysterols for the diagnosis and evaluation of patients with neurological and neurodegenerative diseases. Karolinska Institutel Thesis, Stockholm, Sweden, 2005. cited by applicant
Linseisen J, et al. Plasma 7beta-hydroxycholesterol as a possible predictor of lung cancer risk. Cancer Epidemoil Prev, 2002;11:1630-1637. cited by applicant
Lizard G, et al. Characterization and Comparison of the Mode of Cell Death . . . by 7beta-Hydroxycholesterol and 7-Ketocholesterol in the Cells of the Vascular Wall. Arteriosclerosis, Thrombosis and Vascular Biology, 1999;19:1190-1200. cited by applicant
Mahadevan V, et al. Preparation of cholesterol esters of long-chain fatty acids and characterization of cholestryl arachidonate. Journal of Lipid Research, 1962;3:106-110. cited by applicant
Marcu L, et al. Arterial flourescent components involved in artherosclerotic plagque instability: differentiation by time-resolved flourescence spectroscopy, 2001. cited by applicant
McCourt MP, et al. X-ray crystal structure of cytotoxic oxidized cholesterols: 7-ketocholesterol and 25-hydroxycholesterol. Journal of Lipid Research, 1997;38:1014-1021. cited by applicant
Micheletta F, et al. Vitamin E Supplementation in Patients with Carotid Atherosclerosis. Arterioschlerosis, Thrombosis, and Vascular Biology, 2004;24:136. cited by applicant
Nelson DL, et al. Lehninger Principels of Biochemistry fourthedition. New York: WH Freeman and Company, 2005. cited by applicant
Raff LM. Principles of Physical Chemistry. Upper Sakkle River, NJ: Prentice Hall (2001). cited by applicant
Ringseis R, et al. Insufficient dietary vitamin e increases the concentration of 7beta-hydroxycholesterol in tissues of rats feed salmon oil. The Journal of Nutrition, 2002;132:2732-2735. cited by applicant
Rodriguez IR, et al. Cytotoxicity of Oxidized Low-Density Lipoprotein in Cultures RPE Cells is Dependent on the Formation of 7-Ketocholestrol. Investigative Ophthalmology and Visual Science, 2004;45:2830-2837. cited by applicant
Shands Health Care. Transcient ischemic attack (TIA). 2006. http://www.shands.org/health/information/article/000730.htm. cited by applicant
Sigma-Aldrich Corporation. Material Safety Data Sheet, 2006, http://www.sigma.com. cited by applicant
Tontonoz PA, et al. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor [gamme]: implications for cardiovascular disease. Current Opinion in Lipidology, 1999;10:485-490. cited by applicant
Wikipedia. Apoptosis (2006), http://en.wikipedia.org/wiki/Apoptosis. cited by applicant
Wohlfeil ER, et al. 25-Hydroxycholesterol Increases Eicosanoids and Alters Morphology in Cultures Pulmonary Artery Smooth Muscle and Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999;19:2901-2908. cited by applicant
Funakoshi K, et al. Formation of Giant Lipid Vesiclelike Compartments from a Planar Lipid Membrane by a Pulsed Jet Flow. J Am Chem Soc, 2007;129:12608-12609. cited by applicant
Frankenburg S, et al. Recombinant hydrophilic human gp100: uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients. Immunology Letters, 2004;94:253-259. cited by applicant
Sahin NO. Niosomes as Nanocarrier Systems. IN: Nanomaterials and Nanosystems for Biomedical Applications. Edited by M. Mozafari Netherlands. Springer press, 2007, Chapter 4: p. 67-81. cited by applicant
Prasad S, et al. Polymer nanoparticles containing lysates as antigen delivery vehicles for dendritic cell-bases anti-tumor immunotherapy. Nanomedicine, 2011;7(1):1-10. cited by applicant
Lochmatter P, et al. Drug-specific in vitro release of IL-2, IL-5, IL-13, and IFN-gamma in patients with delayed-type drug hypersensitivity. Allergy, 2009;64(9):1269-1278. cited by applicant
Huan Xu, et al. Preparation and Characterization of pH-Sensitive Vesicles Made of Cholesteryl Hemisuccinate. Drug Development and Industrial Pharmacy, 2008;34(2):134-141. cited by applicant

edspgr.12005146